4152 Taiwan Liposome

TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19

TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
EN
07/10/2020

Underlying

4152Taiwan Liposome

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taiwan Liposome

 PRESS RELEASE
Free
4152 TAIWAN LIPOSOME

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Break...

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. TLC599 is an investigational therapy developed by TLC BioSciences for osteoarthritis knee pain. In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis...

November 20, 2023 1 EN
 PRESS RELEASE
Free
4152 TAIWAN LIPOSOME

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Sessi...

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) --  (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Con...

November 8, 2023 1 EN
 PRESS RELEASE
Free
4152 TAIWAN LIPOSOME

TLC Announces TLC599 Agreement with Endo

TLC Announces TLC599 Agreement with Endo One of the largest deals seen in Taiwan’s biotech sector SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with (Nasdaq: ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the ...

June 13, 2022 1 EN
 PRESS RELEASE
Free
4152 TAIWAN LIPOSOME

TLC BioSciences Announces Publication of TLC599 Phase II Results in Ar...

TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have...

March 7, 2022 1 EN
 PRESS RELEASE
Free
4152 TAIWAN LIPOSOME

TLC Announces Voluntary Delisting and Deregistration of American Depos...

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from th...

September 8, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch